RU2644258C2 - Способы и материалы для лечения болезни помпе - Google Patents
Способы и материалы для лечения болезни помпе Download PDFInfo
- Publication number
- RU2644258C2 RU2644258C2 RU2014139953A RU2014139953A RU2644258C2 RU 2644258 C2 RU2644258 C2 RU 2644258C2 RU 2014139953 A RU2014139953 A RU 2014139953A RU 2014139953 A RU2014139953 A RU 2014139953A RU 2644258 C2 RU2644258 C2 RU 2644258C2
- Authority
- RU
- Russia
- Prior art keywords
- amino acid
- polypeptide
- mannose
- seq
- gaa
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2405—Glucanases
- C12N9/2451—Glucanases acting on alpha-1,6-glucosidic bonds
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
- C12N9/62—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from Aspergillus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01003—Glucan 1,4-alpha-glucosidase (3.2.1.3), i.e. glucoamylase
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Botany (AREA)
- Tropical Medicine & Parasitology (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261611485P | 2012-03-15 | 2012-03-15 | |
| US61/611,485 | 2012-03-15 | ||
| PCT/IB2013/000912 WO2013136189A2 (en) | 2012-03-15 | 2013-03-14 | Methods and materials for treatment of pompe's disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2014139953A RU2014139953A (ru) | 2016-05-20 |
| RU2644258C2 true RU2644258C2 (ru) | 2018-02-08 |
Family
ID=48626475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2014139953A RU2644258C2 (ru) | 2012-03-15 | 2013-03-14 | Способы и материалы для лечения болезни помпе |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US9249399B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2825193B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6194324B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20190114003A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104379162B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013234042B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014022624A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2867237C (cg-RX-API-DMAC7.html) |
| RU (1) | RU2644258C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013136189A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5967861B2 (ja) | 2007-04-03 | 2016-08-10 | オキシレイン ユーケー リミテッド | 分子のグリコシル化 |
| KR102000383B1 (ko) | 2009-09-29 | 2019-07-15 | 유니버시테이트 젠트 | 만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해 |
| US20130053550A1 (en) | 2009-11-19 | 2013-02-28 | Oxyrane Uk Limited | Yeast strains producing mammalian-like complex n-glycans |
| BR112013007616B1 (pt) | 2010-09-29 | 2023-01-24 | Oxyrane Uk Limited | Métodos para retirar o cap ("uncapping") de porções de manose-1- fosfo-6-manose e desmanosilar n-glicanos fosforilados em uma glicoproteína, para direcionar uma glicoproteína para o interior de uma célula de mamífero, e para converter uma glicoproteína de uma primeira forma que não se liga substancialmente a um receptor de manose-6-fosfato em uma segunda forma que se liga substancialmente a um receptor de manose-6-fosfato em uma célula de mamífero |
| JP6131190B2 (ja) | 2010-09-29 | 2017-05-17 | オキシレイン ユーケー リミテッド | リン酸化n−グリカンの脱マンノシル化 |
| CA2867237C (en) | 2012-03-15 | 2024-01-02 | Wouter Vervecken | Methods and materials for treatment of pompe's disease |
| KR20180088919A (ko) | 2015-12-24 | 2018-08-07 | 옥시레인 유케이 리미티드 | 인간 알파-n-아세틸갈락토사미니다아제 폴리펩티드 |
| IL299470B2 (en) | 2015-12-30 | 2026-05-01 | Amicus Therapeutics Inc | Improved acid alpha-glucosidase for the treatment of Pompe disease |
| EP4793349A2 (en) * | 2016-03-30 | 2026-08-19 | Amicus Therapeutics, Inc. | Method for selection of high m6p recombinant proteins |
| KR102618519B1 (ko) * | 2016-03-30 | 2023-12-28 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 산 알파-글루코시다제를 포함하는 제형 |
| CA3019354A1 (en) * | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Method for selection of high m6p recombinant proteins |
| EA039750B1 (ru) * | 2017-03-30 | 2022-03-10 | Амикус Терапьютикс, Инк. | Способ отбора рекомбинантных белков с высоким содержанием m6p |
| CN119113091A (zh) | 2017-05-15 | 2024-12-13 | 阿米库斯治疗学公司 | 重组人类酸性α-葡萄糖苷酶 |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| EP3830259A4 (en) | 2018-08-02 | 2022-05-04 | Dyne Therapeutics, Inc. | MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY |
| WO2020157248A1 (en) | 2019-02-01 | 2020-08-06 | Oxyrane Uk Ltd | Glucocerebrosidase polypeptides |
| JP2024506346A (ja) * | 2021-02-11 | 2024-02-13 | アミカス セラピューティックス インコーポレイテッド | 組換えヒト酸性アルファグルコシダーゼ及びその使用 |
| AU2024347196A1 (en) * | 2023-09-22 | 2026-04-02 | Jfr Co., Ltd. | Method for producing opioid peptide, method for improving production efficiency of opioid peptide, and alkaline protease composition for producing opioid peptide |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2005123986A (ru) * | 2003-01-22 | 2007-02-27 | Гликарт Биотекнолоджи АГ (CH) | Конструкции слияния и их применение для получения антител с повышенными аффинностью связывания fc-рецептора и эффекторной функцией |
| EA012617B1 (ru) * | 2005-03-24 | 2009-10-30 | ДСМ АйПи АССЕТС Б.В. | Способ микробиального производства ценного соединения |
| WO2011039634A2 (en) * | 2009-09-29 | 2011-04-07 | Universiteit Gent | Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4307717A (en) | 1977-11-07 | 1981-12-29 | Lectec Corporation | Sterile improved bandage containing a medicament |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| US4352883A (en) | 1979-03-28 | 1982-10-05 | Damon Corporation | Encapsulation of biological material |
| JPS5754588A (en) | 1980-09-19 | 1982-04-01 | Eiji Ichijima | Alpha-mannosidase |
| US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
| US4407957A (en) | 1981-03-13 | 1983-10-04 | Damon Corporation | Reversible microencapsulation of a core material |
| US4837148A (en) | 1984-10-30 | 1989-06-06 | Phillips Petroleum Company | Autonomous replication sequences for yeast strains of the genus pichia |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
| US4883666A (en) | 1987-04-29 | 1989-11-28 | Massachusetts Institute Of Technology | Controlled drug delivery system for treatment of neural disorders |
| US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
| US5158881A (en) | 1987-11-17 | 1992-10-27 | Brown University Research Foundation | Method and system for encapsulating cells in a tubular extrudate in separate cell compartments |
| US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
| DE3829752A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Integrale asymmetrische polyaethersulfonmembran, verfahren zur herstellung und verwendung zur ultrafiltration und mikrofiltration |
| DE3829766A1 (de) | 1988-09-01 | 1990-03-22 | Akzo Gmbh | Verfahren zur herstellung von membranen |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5084350A (en) | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
| US5272070A (en) | 1991-03-08 | 1993-12-21 | Board Of Regents, The University Of Texas System | Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby |
| SG47470A1 (en) | 1991-04-25 | 1998-04-17 | Univ Brown Res Found | Implantable biocompatible immunoisolatory vehicle for delivery of a selected therapeutic products |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US6042828A (en) | 1992-09-07 | 2000-03-28 | Kyowa Hakko Kogyo Co., Ltd. | Humanized antibodies to ganglioside GM2 |
| ES2178654T3 (es) | 1993-08-12 | 2003-01-01 | Neurotech Sa | Capsulas biocompatibles inmonoaisladoras que contienen celulas geneticamente alteradas para el suministro de moleculas biologicamente activas. |
| US5589359A (en) | 1994-08-05 | 1996-12-31 | Chiron Corporation | Chimeric proteins |
| US5834251A (en) | 1994-12-30 | 1998-11-10 | Alko Group Ltd. | Methods of modifying carbohydrate moieties |
| EP0922109A1 (en) | 1996-05-21 | 1999-06-16 | Novo Nordisk A/S | Novel yeast promoters suitable for expression cloning in yeast and heterologous expression of proteins in yeast |
| US6699658B1 (en) | 1996-05-31 | 2004-03-02 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| US6300065B1 (en) | 1996-05-31 | 2001-10-09 | Board Of Trustees Of The University Of Illinois | Yeast cell surface display of proteins and uses thereof |
| EP0909312B1 (en) | 1996-07-05 | 2002-12-04 | Novo Nordisk A/S | Method for the production of polypeptides |
| US6110703A (en) | 1996-07-05 | 2000-08-29 | Novo Nordisk A/S | Method for the production of polypeptides |
| WO1998001473A1 (en) | 1996-07-05 | 1998-01-15 | Novo Nordisk A/S | Method for the production of precursors of insulin, precursors of insulin analogues, and insulin like peptides |
| JP2001526533A (ja) | 1997-04-23 | 2001-12-18 | フラームス・インテルウニフェルシタイル・インスティチュート・フォール・ビオテヒノロヒー | λ様プロモーターを有する遺伝子の誘導性発現のための調節系 |
| US7442772B2 (en) | 1997-12-03 | 2008-10-28 | Genentech, Inc. | Antibodies to PRO361 polypeptide |
| WO1999037758A2 (en) | 1998-01-27 | 1999-07-29 | The Board Of Regents Of The University And Community College System Of Nevada On Behalf Of The University Of Nevada-Reno | Expression of proteolytically-sensitive peptides |
| WO2001042462A2 (en) | 1999-12-08 | 2001-06-14 | National University Of Singapore | Phospholipase a2 inhibitory peptides from python reticulatus |
| US20020127219A1 (en) * | 1999-12-30 | 2002-09-12 | Okkels Jens Sigurd | Lysosomal enzymes and lysosomal enzyme activators |
| IL150314A0 (en) | 1999-12-30 | 2002-12-01 | Maxygen Aps | Improved lysosomal enzymes and lysosomal enzyme activators |
| WO2001088143A1 (en) | 2000-05-17 | 2001-11-22 | Mitsubishi Pharma Corporation | Process for producing protein with reduction of acidic sugar chain and glycoprotein produced thereby |
| US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
| US7863020B2 (en) | 2000-06-28 | 2011-01-04 | Glycofi, Inc. | Production of sialylated N-glycans in lower eukaryotes |
| US7598055B2 (en) | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
| US7795002B2 (en) | 2000-06-28 | 2010-09-14 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
| US8697394B2 (en) | 2000-06-28 | 2014-04-15 | Glycofi, Inc. | Production of modified glycoproteins having multiple antennary structures |
| US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
| US7029872B2 (en) | 2000-06-28 | 2006-04-18 | Glycofi, Inc | Methods for producing modified glycoproteins |
| EP2028275A3 (en) | 2000-06-30 | 2009-05-06 | VIB vzw | Protein glycosylation modification in pichia pastoris |
| ES2258371B1 (es) | 2000-08-31 | 2007-05-16 | Dong Kook Pharmaceutical Co. Ltd. | Levadura transformante productora de hormona paratiroidea humana y procedimiento para producir la hormona. |
| US7001994B2 (en) | 2001-01-18 | 2006-02-21 | Genzyme Corporation | Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins |
| JP4774496B2 (ja) | 2001-06-14 | 2011-09-14 | 独立行政法人産業技術総合研究所 | α−マンノシダーゼ |
| JP4742191B2 (ja) | 2001-06-14 | 2011-08-10 | 独立行政法人産業技術総合研究所 | 糖蛋白質およびその製造方法 |
| US20030186374A1 (en) | 2001-10-01 | 2003-10-02 | Hufton Simon E. | Multi-chain eukaryotic display vectors and uses thereof |
| US7473680B2 (en) | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
| CA2471551C (en) | 2001-12-27 | 2014-09-30 | Glycofi, Inc. | Methods to engineer mammalian-type carbohydrate structures |
| ES2327830T3 (es) | 2002-03-29 | 2009-11-04 | Schering Corporation | Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen. |
| JP4464269B2 (ja) | 2002-04-26 | 2010-05-19 | 協和発酵キリン株式会社 | 哺乳類型糖鎖生産メチロトロフ酵母 |
| US7252933B2 (en) | 2002-06-26 | 2007-08-07 | Flanders Interuniversity Institute For Biotechnology | Protein glycosylation modification in methylotrophic yeast |
| EP1534835B1 (en) | 2002-06-29 | 2010-09-08 | Korea Research Institute of Bioscience and Biotechnology | Hansenula polymorpha yapsin deficient mutant strain and process for the preparation of recombinant proteins using the same |
| KR100470978B1 (ko) | 2003-01-02 | 2005-03-10 | 한국생명공학연구원 | 앱신 다중 결손 효모 변이 균주 및 이를 이용한 재조합 단백질의 생산 방법 |
| AU2012206984B2 (en) | 2003-02-11 | 2015-07-09 | Takeda Pharmaceutical Company Limited | Diagnosis and treatment of multiple sulfatase deficiency and other using a formylglycine generating enzyme (FGE) |
| JP4259169B2 (ja) | 2003-04-16 | 2009-04-30 | 昭和産業株式会社 | 新規α−1,2−マンノシダーゼおよびその遺伝子、ならびに該酵素を用いたα−マンノシル糖化合物の製造方法 |
| US7259255B2 (en) | 2003-06-25 | 2007-08-21 | E. I. Du Pont De Nemours And Company | Glyceraldehyde-3-phosphate dehydrogenase and phosphoglycerate mutase promoters for gene expression in oleaginous yeast |
| EP1696864B1 (en) | 2003-12-24 | 2014-11-12 | GlycoFi, Inc. | Methods for eliminating mannosylphosphorylation of glycans in the production of glycoproteins |
| DE602005020745D1 (de) | 2004-02-10 | 2010-06-02 | Zystor Therapeutics Inc | Saure alpha-glukosidase und fragmente davon |
| WO2005089047A2 (en) | 2004-03-18 | 2005-09-29 | Glycofi, Inc. | Glycosylated glucocerebrosidase expression in fungal hosts |
| JP2007535317A (ja) | 2004-04-15 | 2007-12-06 | グライコフィ, インコーポレイテッド | 下等真核生物におけるガラクトシル化された糖タンパク質の産生 |
| JP4954866B2 (ja) | 2004-04-29 | 2012-06-20 | グライコフィ, インコーポレイテッド | 糖タンパク質の作製においてアルファ−マンノシダーゼ抵抗性グリカンを減少させるか又は排除する方法 |
| CA2501422C (en) | 2004-04-29 | 2014-08-12 | University Of Rochester | Lymphoid chemokines in the diagnosis, monitoring and treatment of autoimmune disease |
| US20060014264A1 (en) | 2004-07-13 | 2006-01-19 | Stowers Institute For Medical Research | Cre/lox system with lox sites having an extended spacer region |
| US7431927B2 (en) | 2005-03-24 | 2008-10-07 | Epitomics, Inc. | TNFα-neutralizing antibodies |
| WO2007010403A2 (en) | 2005-04-14 | 2007-01-25 | Scir | Recombinant yeasts for synthesizing epoxide hydrolases |
| US8202523B2 (en) | 2005-09-22 | 2012-06-19 | ProSci, Inc. | Glycosylated polypeptides produced in yeast mutants and methods of use thereof |
| US20080081035A1 (en) * | 2006-10-03 | 2008-04-03 | National Enzyme Company | Therapeutic protease compositions |
| EP2068914A4 (en) | 2007-02-09 | 2011-07-20 | Medimmune Llc | PRESENTATION OF ANTIBODY BANK BY PLASMA MEMBRANES OF YEAST CELLS |
| JP5967861B2 (ja) | 2007-04-03 | 2016-08-10 | オキシレイン ユーケー リミテッド | 分子のグリコシル化 |
| US8569032B2 (en) | 2007-05-18 | 2013-10-29 | Tokyo Metropolitan Institute Of Medical Science | Proteins having acquired A-galactosidase activity |
| PL3219795T3 (pl) | 2008-01-18 | 2024-09-16 | Biomarin Pharmaceutical Inc. | Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania |
| JP2011514157A (ja) | 2008-02-20 | 2011-05-06 | グライコフィ, インコーポレイテッド | 蛋白質生産用ベクター及び酵母株 |
| WO2009137721A2 (en) * | 2008-05-07 | 2009-11-12 | Zystor Therapeutics, Inc. | Lysosomal targeting peptides and uses thereof |
| JP2012518999A (ja) | 2009-02-26 | 2012-08-23 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 宿主細胞およびその使用方法 |
| US20130053550A1 (en) | 2009-11-19 | 2013-02-28 | Oxyrane Uk Limited | Yeast strains producing mammalian-like complex n-glycans |
| FR2954349A1 (fr) | 2009-12-22 | 2011-06-24 | Agronomique Inst Nat Rech | Sulfatase modifiant selectivement les glycosaminoglycanes |
| US20130096281A1 (en) | 2010-01-21 | 2013-04-18 | Oxyrane Uk Limited | Methods and compositions for displaying a polypeptide on a yeast cell surface |
| US20120135461A1 (en) | 2010-07-30 | 2012-05-31 | William James Cook | Production of glycoproteins with reduced o-glycosylation comprising the use of an alpha-1,2-mannosidase |
| BR112013007616B1 (pt) | 2010-09-29 | 2023-01-24 | Oxyrane Uk Limited | Métodos para retirar o cap ("uncapping") de porções de manose-1- fosfo-6-manose e desmanosilar n-glicanos fosforilados em uma glicoproteína, para direcionar uma glicoproteína para o interior de uma célula de mamífero, e para converter uma glicoproteína de uma primeira forma que não se liga substancialmente a um receptor de manose-6-fosfato em uma segunda forma que se liga substancialmente a um receptor de manose-6-fosfato em uma célula de mamífero |
| JP6131190B2 (ja) | 2010-09-29 | 2017-05-17 | オキシレイン ユーケー リミテッド | リン酸化n−グリカンの脱マンノシル化 |
| JP2015503338A (ja) | 2011-12-30 | 2015-02-02 | オキシレイン ユーケー リミテッド | 組換えタンパク質の分解を低減させる方法および材料 |
| CA2867237C (en) | 2012-03-15 | 2024-01-02 | Wouter Vervecken | Methods and materials for treatment of pompe's disease |
-
2013
- 2013-03-14 CA CA2867237A patent/CA2867237C/en active Active
- 2013-03-14 EP EP13729065.6A patent/EP2825193B1/en active Active
- 2013-03-14 US US13/831,368 patent/US9249399B2/en active Active
- 2013-03-14 KR KR1020197028133A patent/KR20190114003A/ko not_active Ceased
- 2013-03-14 JP JP2014561541A patent/JP6194324B2/ja not_active Expired - Fee Related
- 2013-03-14 CN CN201380024824.6A patent/CN104379162B/zh not_active Expired - Fee Related
- 2013-03-14 RU RU2014139953A patent/RU2644258C2/ru active
- 2013-03-14 KR KR1020147027709A patent/KR102028228B1/ko not_active Expired - Fee Related
- 2013-03-14 BR BR112014022624A patent/BR112014022624A2/pt not_active Application Discontinuation
- 2013-03-14 EP EP19207930.9A patent/EP3628326B1/en active Active
- 2013-03-14 AU AU2013234042A patent/AU2013234042B2/en not_active Ceased
- 2013-03-14 WO PCT/IB2013/000912 patent/WO2013136189A2/en not_active Ceased
-
2015
- 2015-12-28 US US14/981,123 patent/US10648044B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2005123986A (ru) * | 2003-01-22 | 2007-02-27 | Гликарт Биотекнолоджи АГ (CH) | Конструкции слияния и их применение для получения антител с повышенными аффинностью связывания fc-рецептора и эффекторной функцией |
| EA012617B1 (ru) * | 2005-03-24 | 2009-10-30 | ДСМ АйПи АССЕТС Б.В. | Способ микробиального производства ценного соединения |
| WO2011039634A2 (en) * | 2009-09-29 | 2011-04-07 | Universiteit Gent | Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose |
Non-Patent Citations (6)
| Title |
|---|
| BIJVOET A. G. A. et al., Recombinant human acid α-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice, Human Molecular Genetics, Vol.7, NO.11, pp.1815-1824, 1998. * |
| HIROKI TATSUMI et al., Cloning and Sequencing of the Alkaline Protease cDNA from Aspergillus oryzae, Vol.52, Issue 7, pp.1887-1888, 1988. * |
| JOHAN L. K. VAN HOVE et al., High-level production of recombinant human lysosomal acid α-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease, Proceedings of the National Academy of Sciences, Vol.93, NO.1, pp.65-70, 1996. * |
| MORELAND R. J. et al., Lysosomal Acid alpha-Glucosidase Consists of Four Different Peptides Processed from a Single Chain Precursor, The Journal of Biological Chemistry, Vol.280, No.8, pp.6780-6791, 2005. * |
| ZHU Y. et al., Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease, Molecular Therapy, Vol.17, NO.6, pp.954-963, 2009. * |
| ZHU Y. et al., Glycoengineered Acid α-Glucosidase With Improved Efficacy at Correcting the Metabolic Aberrations and Motor Function Deficits in a Mouse Model of Pompe Disease, Molecular Therapy, Vol.17, NO.6, pp.954-963, 2009. BIJVOET A. G. A. et al., Recombinant human acid α-glucosidase: high level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice, Human Molecular Genetics, Vol.7, NO.11, pp.1815-1824, 1998. JOHAN L. K. VAN HOVE et al., High-level production of recombinant human lysosomal acid α-glucosidase in Chinese hamster ovary cells which targets to heart muscle and corrects glycogen accumulation in fibroblasts from patients with Pompe disease, Proceedings of the National Academy of Sciences, Vol.93, NO.1, pp.65-70, 1996. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP6194324B2 (ja) | 2017-09-06 |
| CN104379162A (zh) | 2015-02-25 |
| WO2013136189A2 (en) | 2013-09-19 |
| US20160279254A1 (en) | 2016-09-29 |
| AU2013234042A1 (en) | 2014-10-23 |
| CA2867237C (en) | 2024-01-02 |
| EP2825193B1 (en) | 2019-11-13 |
| JP2015516148A (ja) | 2015-06-11 |
| EP3628326B1 (en) | 2024-02-28 |
| AU2013234042B2 (en) | 2017-11-02 |
| KR20140135802A (ko) | 2014-11-26 |
| RU2014139953A (ru) | 2016-05-20 |
| HK1200348A1 (en) | 2015-08-07 |
| CA2867237A1 (en) | 2013-09-19 |
| EP3628326A1 (en) | 2020-04-01 |
| US10648044B2 (en) | 2020-05-12 |
| KR102028228B1 (ko) | 2019-10-04 |
| EP3628326C0 (en) | 2024-02-28 |
| US20130243746A1 (en) | 2013-09-19 |
| WO2013136189A3 (en) | 2014-02-20 |
| US9249399B2 (en) | 2016-02-02 |
| EP2825193A2 (en) | 2015-01-21 |
| KR20190114003A (ko) | 2019-10-08 |
| BR112014022624A2 (pt) | 2017-07-11 |
| CN104379162B (zh) | 2017-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10648044B2 (en) | Methods and materials for treatment of Pompe's disease | |
| US10392609B2 (en) | Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose | |
| KR101983572B1 (ko) | 만노스-1-포스포-6-만노스 결합의 캡핑제거 및 인산화 n-글리칸의 탈만노실이 가능한 만노시다제 및 당단백질의 활용을 통한 포유류 세포의 촉진방법 | |
| US20220204952A1 (en) | Production of catalytically active type i sulfatase | |
| EP3393501B1 (en) | Human alpha-n-acetylgalactosaminidase polypeptide | |
| HK1200348B (en) | Methods and materials for treatment of pompe's disease | |
| HK1171248A (en) | Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose |